Analyst Thinks MannKind’s (MNKD) Afrezza Still Has a Shot, Though Q3 Earnings Hit Below Guidance

Despite MannKind (MNKD) reporting third-quarter revenue for diabetes drug Afrezza below H.C.

H.C. Wainwright Reiterates Buy on MannKind (MNKD) Stock as TreT Unveiled to Broader Audience at United’s Science Day

Yesterday, United Therapeutics (UTHR), MannKind’s (MNKD) partner for Technosphere treprostinil (TreT), hosted its Science Day 2018. MannKind’s dry powder inhalable treprostinil formulation for …

H.C. Wainwright Reiterates Upbeat View of MannKind; Here’s Why

This week, MannKind (MNKD) announced a global partnership with United Therapeutics (UTHR) to develop and commercialize Technosphere treprostinil (TreT) dry powder inhalation for …

MannKind (MNKD): Shoring up the Balance Sheet by Selling Stock Comes with a Price

Shares of biotechnology company MannKind (NASDAQ:MNKD) are taking a hit – down nearly 25% as of this writing. The reason?

This Analyst Sounds the Alarm on MannKind Corporation (MNKD)

What do you do when a company has “more debt than assets?” Maxim’s Jason Kolbert just lost patience with MNKD.

Hedge Fund Tycoon David Shaw Makes 2 Risky Bio Bets: MannKind Corporation (MNKD), Valeant Pharmaceuticals Intl Inc (VRX)

Chief scientist Shaw looks for unusual sources of return in MNKD and VRX.

MannKind Corporation Appoints Dr. David Kendall as Chief Medical Officer

MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts